Clinical trials: Dysthyroid Orbitopathy
Graves Ophthalmopathy
Glucocorticoids and Bone in Graves' Ophthalmopathy
Continuous use of systemic glucocorticoids decreases bone mineral density and increases fracture risk. Graves' orbitopathy is treated with weekly infusion of high-dose intravenous glucocorticoid.
- Trial name
- NCT03122847
- Testing
- Methylprednisolone
- Where
- 2 sites in Denmark
- Volunteers
- 39 people
- Sponsor
- Torben Harsløf
Thyroid Eye Disease
AS-OCT of the Cornea in Thyroid Diseases
use the anterior segment optical coherence tomography (AS-OCT) to evaluate the tear meniscus parameters, total corneal thickness (CT), and epithelial thickness in active and inactive thyroid eye diseases (TED) patients and…
- Trial name
- NCT05241626
- Testing
- AS-OCT
- Where
- 2 sites in Egypt
- Volunteers
- 70 people
- Sponsor
- Minia University
Thyroid Associated Ophthalmopathy
Natural History and Risk Factors of TAO
The aim of this study is to complete the identification of genetic factors predisposing to thyroid associated ophthalmopathy (TAO) by constituting a cohort of 400 Grave's patients with or without ocular signs.
- Trial name
- NCT03515863
- Testing
- DNA extraction and genetic characterization, Orbit MRI examination, Collection of life style data
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Graves Ophthalmopathy
Hydroxychloroquine in Mild Graves' Orbitopathy
This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).
- Trial name
- NCT05126147
- Testing
- Hydroxychloroquine
- Where
- 2 sites in Taiwan
- Volunteers
- 108 people
- Sponsor
- National Taiwan University Hospital
Thyroid Eye Disease
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
The investigational drug, ZB001 is a humanized IgG1κ monoclonal antibody targeting human IGF-1R. The study is designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics（PK）/pharmacodynamics (PD) profile of…
- Trial name
- NCT05776121
- Testing
- ZB001 for injection
- Where
- 9 sites in China
- Volunteers
- 17 people
- Sponsor
- Zenas BioPharma (USA), LLC
Thyroid Eye Disease (TED)
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)
- Trial name
- NCT07211776
- Testing
- ZL-1109 (VRDN-003)
- Where
- 26 sites in China
- Volunteers
- 108 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Graves' Ophthalmopathy
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
The purpose of the study is to establish whether Bimatoprost eye drops are effective in reducing proptosis in inactive thyroid eye disease (TED) patients and improving quality of life in patients with TED.
- Trial name
- BIMA (NCT02059655)
- Testing
- Bimatoprost, Eye drop solution
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Cardiff University
Graves' Ophthalmopathy
The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves'Ophthalmopathy
The exact mechanism of the pathogenesis of Graves' ophthalmopathy is still unknown. Histopathologically, extraocular muscle inflammation and orbital fat inflammation are two prominent changes.
- Trial name
- NCT00174057
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Thyroid Eye Disease, Graves' Orbitopathy
Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study
The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (a fully human monoclonal antibody [mAb] inhibitor of the insulin-like growth factor-1 receptor [IGF-1R]) administered once every 3…
- Trial name
- OPTIC (NCT03298867)
- Testing
- Teprotumumab
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 83 people
- Sponsor
- Amgen
Keratoconus, Corneal Ectasia
Corneal Tomographic Parameters in TGD
The current study involved analysis of the corneal tomographic parameters of patients with thyroid gland dysfunction (hyperthyroidism or hypothyroidism), including those with an autoimmune etiology, in comparison to healthy…
- Conditions
- Keratoconus, Corneal Ectasia, Thyroid Eye Disease
- Trial name
- NCT04433936
- Testing
- Pentacam tomography
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ameera Gamal Abdelhameed
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Patients With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07620405
- Testing
- MHB018A injection
- Volunteers
- 219 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves' Ophthalmopathy
A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy
This study was designed to compare the efficacy and safety of 4.5g iv MP administered in 12 weeks and 4 weeks.
- Trial name
- NCT01969019
- Testing
- methylprednisolone, prednisone
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Ruijin Hospital
Graves´ Disease
Adjuvant Treatment of Graves´ Ophthalmopathy With NSAID (aGO Study)
AGO study - adjuvant treatment, with NSAID, of endocrine ophthalmopathy in Graves´ disease Background - Already at diagnosis of Graves disease approximately 98% of the patients have morphological changes of the retrobulbar tissue…
- Trial name
- aGO (NCT01458600)
- Testing
- Diclofenac, Methimazole, L-thyroxin
- Where
- 3 sites in Sweden
- Volunteers
- 65 people
- Sponsor
- Mikael Lantz
Pulmonary Fibrosis, Thyroid Eye Disease
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED.
- Trial name
- NCT05331300
- Testing
- LASN01
- Where
- 4 sites in Australia, Hong Kong
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Lassen Therapeutics 1 PTY LTD
Thyroid Eye Disease
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial…
- Trial name
- HAZEL 401 (NCT07438405)
- Testing
- AMG 732
- Where
- 8 sites in United States, Poland and 2 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Graves' Ophthalmopathy (GO)
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants.
- Trial name
- NCT03938545
- Testing
- RVT-1401 (Administered via subcutaneous injection)
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Immunovant Sciences GmbH
Thyroid Eye Disease
TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study
This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants.
- Trial name
- NCT05002998
- Testing
- Teprotumumab
- Where
- 28 sites in United States, France and 4 more
- Volunteers
- 313 people
- Sponsor
- Amgen
Thyroid Associated Ophthalmopathy, Hypercholesterolemia
Effects of Atorvastatin in Graves' Orbitopathy (GO)
Graves' orbitopathy (GO) is the most common extra-thyroidal manifestation of Graves' disease (GD), being observed in ~25% of patients.
- Trial name
- STAGO (NCT03110848)
- Testing
- Atorvastatin, Methylprednisolone
- Where
- Italy
- Volunteers
- 88 people
- Sponsor
- University of Pisa
TED
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.
Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease
- Trial name
- NCT06769984
- Testing
- SCTT11
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Thyroid Eye Disease, Ocular Hypertension
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients.
- Conditions
- Thyroid Eye Disease, Ocular Hypertension, Glaucoma
- Trial name
- NCT01927406
- Testing
- Prostaglandin Analog, Timolol
- Where
- United States
- Sponsor
- Stanford University